Core Viewpoint - Sillodic Pharmaceuticals (01244) has seen a significant stock increase of over 10%, currently up 13.96% at HKD 9.06, with a trading volume of HKD 17.58 million, following the announcement of its first radioactive nuclide conjugated drug (RDC) 177Lu-PSMA-3D1015 injection completing the first patient dosing in IIT research [1] Company Summary - The company has announced that its self-developed nuclear medicine platform's first product, 177Lu-PSMA-3D1015 injection, has completed the first patient dosing in an IIT study aimed at evaluating its safety and preliminary efficacy for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The injection is expected to have "best-in-class" potential and aims to provide a safer and more effective treatment option for prostate cancer patients globally, thereby advancing China's nuclear medicine research to an internationally leading level [1] Industry Summary - According to MEDraysintell, the global nuclear medicine market is projected to reach nearly USD 39 billion by 2032 [1]
港股异动 | 思路迪医药股份(01244)涨超10% 自主研发新一代精准核药完成首例患者给药 核药市场潜力巨大